Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Beclabuvir

Alternative Names: beclabuvir, bms-791325, bms791325, bms 791325
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymerase (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123187/)

Mechanisms of Action: HCV-NS5B Inhibitor,NN Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hepatitis C, Chronic

Phase 3: Hepatitis C, Chronic|Hepatitis A|Hepatitis C

Phase 1: Hepatitis C

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
HEPCOG-II

P4

Withdrawn

Hepatitis C, Chronic

2016-06-01

RHACE 1

N/A

Completed

Hepatitis A|Hepatitis C

2016-02-01

JapicCTI-142546

P3

Completed

Hepatitis C

2016-02-01

UNITY 4

P3

Completed

Hepatitis A|Hepatitis C, Chronic

2015-06-12

Recent News Events

Date

Type

Title

03/01/2024

PubMed

 The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy.

02/22/2024

News Article

 Atomic AI Announces Appointments of New Independent Member to its Board of Directors and Additions to the Scientific Advisory Board

12/01/2023

PubMed

 Novel pseudonucleosides and sulfamoyl-oxazolidinone Ī²-D-glucosamine derivative as anti-COVID-19: design, synthesis, and in silico study.

02/15/2022

PubMed

 Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions